Compare TONX & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TONX | ALXO |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 205.9M |
| IPO Year | 2013 | 2020 |
| Metric | TONX | ALXO |
|---|---|---|
| Price | $3.61 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 269.4K | ★ 930.4K |
| Earning Date | 11-11-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.21 | 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $32,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 433.33 | N/A |
| 52 Week Low | $1.75 | $1.05 |
| 52 Week High | $7.14 | $2.66 |
| Indicator | TONX | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 29.67 |
| Support Level | $2.85 | $1.37 |
| Resistance Level | $3.90 | $1.56 |
| Average True Range (ATR) | 0.26 | 0.10 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 65.78 | 12.32 |
TON Strategy Co is a digital asset treasury and Web3 ecosystem company focused on supporting The Open Network, a public blockchain integrated with Telegram and designed for fast, scalable transactions and decentralized applications. Its core business is managing its holdings of Toncoin (TON), including staking tokens to support network validation and earn rewards, while adhering to regulatory, accounting, and risk management standards. The company also pursues Web3 initiatives to support the ecosystem's growth and adoption. It operates through MARKET. live, Go Fund Yourself, and TON segments, with MARKET.live generating maximum revenue as a multi-vendor livestream shopping platform that combines e-commerce and entertainment across social and video channels.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.